ascendis pharma glp-1 receptor agonist medications Novo Nordisk taps in $285 million deal Novo puts $285m into monthly

Dludla P.V., Joubert E., Muller C.J.F., Louw J., Johnson R

While the pharma industry attempts to expand the improved GLP-1 drug market, including orals, the generics industry will grow its GLP-1 agonist foothold, making cheaper and less efficacious injectable GLP-1 drugs much more widely available, rapidly growing the number of patients comfortable with self-injection for weight loss

Thus, targeting hepatokines to modulate inflammation represents a potential therapeutic approach

Liquid lipo reduces fat by breaking down fat cells in specific areas of the body

For acute concerns like injury recovery, individuals may experience initial relief within a few weeks